102 related articles for article (PubMed ID: 38743600)
1. Zavegepant for Acute Treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Suresh V; Bardhan M; Dave T; Shamim MA; Suresh D; Satish P; Dhakal B; Bhonsale A; Roy P; Padhi BK; Monteith T
Clin Neuropharmacol; 2024 May-Jun 01; 47(3):72-81. PubMed ID: 38743600
[TBL] [Abstract][Full Text] [Related]
2. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
Croop R; Madonia J; Stock DA; Thiry A; Forshaw M; Murphy A; Coric V; Lipton RB
Headache; 2022 Oct; 62(9):1153-1163. PubMed ID: 36239038
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
Lipton RB; Croop R; Stock DA; Madonia J; Forshaw M; Lovegren M; Mosher L; Coric V; Goadsby PJ
Lancet Neurol; 2023 Mar; 22(3):209-217. PubMed ID: 36804093
[TBL] [Abstract][Full Text] [Related]
4. Nasal spray (Zavegepant) for migraines: a mini-review.
Larik MO; Iftekhar MA; Syed BU; Ansari O; Ansari M
Ann Med Surg (Lond); 2023 Jun; 85(6):2787-2790. PubMed ID: 37363553
[TBL] [Abstract][Full Text] [Related]
5. Zavegepant Intranasal Spray for Migraines.
Martirosov AL; Giuliano C; Shupp M; Channey S; Kale-Pradhan PB
Ann Pharmacother; 2023 Oct; ():10600280231209439. PubMed ID: 37897226
[TBL] [Abstract][Full Text] [Related]
6. Zavegepant nasal spray for the acute treatment of migraine: A meta analysis.
Waqas M; Ansari FUR; Nazir A; Hussain KSR; Sarfraz Z; Sarfraz A; Sarfraz M; Kc M
Medicine (Baltimore); 2023 Oct; 102(43):e35632. PubMed ID: 37904462
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis.
Li G; Duan S; Zhu T; Ren Z; Xia H; Wang Z; Liu L; Liu Z
J Headache Pain; 2023 Sep; 24(1):129. PubMed ID: 37723470
[TBL] [Abstract][Full Text] [Related]
9. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review.
Khan ZZ; Ahmed U; Shahzad F; Ali M; Tousif K; Ahmed U; Muhammad Safwan Q; Naufil SI; Murtaza S; Saeed S; Basit J; Haider T; Shabbir H
Cureus; 2023 Jul; 15(7):e41991. PubMed ID: 37593294
[TBL] [Abstract][Full Text] [Related]
11. Drugs for the acute treatment of migraine in children and adolescents.
Richer L; Billinghurst L; Linsdell MA; Russell K; Vandermeer B; Crumley ET; Durec T; Klassen TP; Hartling L
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD005220. PubMed ID: 27091010
[TBL] [Abstract][Full Text] [Related]
12. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials.
Deng X; Zhou L; Liang C; Shang X; Hui X; Liu W; Liang S; Wang Y; Xu M; Guo K; Yang K; Li X
J Headache Pain; 2024 Feb; 25(1):16. PubMed ID: 38311738
[TBL] [Abstract][Full Text] [Related]
14. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
15. Zolmitriptan for acute migraine attacks in adults.
Bird S; Derry S; Moore RA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD008616. PubMed ID: 24848613
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.
Zhang Z; Shu Y; Diao Y; Du Y; Chen L; Liu Y; Du B
Medicine (Baltimore); 2021 Feb; 100(8):e24741. PubMed ID: 33663087
[TBL] [Abstract][Full Text] [Related]
17. Ubrogepant for the Treatment of Migraine.
Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
[TBL] [Abstract][Full Text] [Related]
18. Zavegepant: First Approval.
Dhillon S
Drugs; 2023 Jun; 83(9):825-831. PubMed ID: 37227596
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis.
Lee S; Staatz CE; Han N; Baek IH
Eur J Clin Pharmacol; 2022 Sep; 78(9):1365-1376. PubMed ID: 35729340
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
